A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study
Authors
Seong Jun Seo (ORCID: https://orcid.org/0000-0003-2915-839X)
A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study
Seong Jun Seo, Jung-Won Shin, Pil-Su Ho, Kyu Han Kim et al.
Local Database Links
1 links
Journal
Frontiers in Immunology
Topics
Dermatology and Skin Diseases
article
A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study
Seong Jun Seo, Jung-Won Shin, Pil-Su Ho, Kyu Han Kim, Bo Ri Kim, Chang Ook Park, Seung‐Yong Seong, Chang‐Hun Huh, Jung‐Im Na, Goo Hyun Baek, Y. Kim, Jungjoong Hwang, Young Soo Kim, Dongyoon Shin, Siwon Kim, Chun Wook Park, Sung-Min Ko
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in ImmunologyVol. 16
Institutions
Seoul National University (KR), Kangwon National University (KR), Yonsei University (KR), Severance Hospital (KR), Society of Health and Physical Educators (US), Seoul National University Bundang Hospital (KR), Hallym University Kangnam Sacred Heart Hospital (KR), Veterans Health Service Medical Center (KR), CHA University (KR), Chung-Ang University (KR)